Acute Kidney Injury Associated With Immune Checkpoint Inhibitors
Researchers at Brigham and Women’s Hospital have identified several links between the use of immune checkpoint inhibitors (ICPIs) and acute kidney injury (AKI). The risk factors, clinicopathologic features, treatment and long-term outcomes in patients with ICPI-associated AKI, as well as the risk of recurrent AKI with ICPI rechallenge, are detailed in a multicenter study recently published in the Journal of the American Society of Nephrology. These newly identified links will help guide oncologists in treating patients with ICPIs.
It can be challenging to assess the effects of dietary changes on a disease, especially when those changes involve eliminating common, often beloved foods from a child’s diet. However, 
Study identifies key factor leading to cell cycle arrest and a cellular structure that is key for kidney fibrosis progression. 
In the 1960s, Brigham and Women’s Hospital pioneered the development and commercialization of dialysis. Once again, the Brigham is on the forefront of renal replacement therapy (RRT) through a new project spearheaded by the Kidney Health Initiative (KHI), a public-private partnership between the 
End-stage kidney disease patients on dialysis need to continue dialysis to stay alive. To reduce the pain and common worries in their final phase of life, they also need access to hospice care. Unfortunately, Medicare patients with end-stage kidney disease often can’t have both.
In the search of a practical screening method for early-stage renal cell cancer (RCC), researchers at Brigham and Women’s Hospital have been studying the potential of kidney injury molecule-1 (KIM-1). Their latest research was 
A new electronic health record (EHR) tool could help physicians quickly and accurately flag patients that should be referred to a nephrologist based on indicators that may signal the risk of kidney failure. Designed by 